(Q46827159)

25 December 2017

review article

1 reference

title

Natural history of factors influencing the severity of chronic HCV infection in HIV-HCV coinfected patients (English)

1 reference

25 December 2017

author name string

Dominique Roulot

series ordinal

1

1 reference

25 December 2017

Anaïs Vallet-Pichard

series ordinal

2

1 reference

25 December 2017

language of work or name

French

0 references

publication date

1 October 2007

1 reference

25 December 2017

Gastroenterologie Clinique et Biologique

published in

1 reference

25 December 2017

volume

31

1 reference

25 December 2017

issue

10

1 reference

25 December 2017

page(s)

881-886

1 reference

25 December 2017

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Fibrosing cholestatic hepatitis after liver transplantation in a patient with hepatitis C and HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

The progression of HCV-associated liver disease in a cohort of haemophilic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

The clinical spectrum of hepatitis C virus in HIV coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2807%2973985-4

7 January 2021

10.1016/S0399-8320(07)73985-4

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017